Formycon Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Stefan Glombitza

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	8.1yrs
Proprietà del CEO	n/a
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Stefan Glombitza (59 yo)

8.1yrs

Mandato

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza served as Chief Operating Officer of Formycon...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefan Glombitza	CEO & Member of Executive Board	8.1yrs	Nessun dato	Nessun dato
Friedrich-Wilhelm Steinweg	Co-Founder	no data	Nessun dato	Nessun dato
Nicolas Combe	Co-Founder	no data	Nessun dato	Nessun dato
Enno Spillner	CFO & Member of Management Board	1.6yrs	Nessun dato	Nessun dato
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	2.3yrs	Nessun dato	Nessun dato
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	2.4yrs	Nessun dato	Nessun dato
Sabrina Muller	Director of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato

2.4yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di 0W4N è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Bernhard Hampl	Member of Advisory Board	10.7yrs	Nessun dato	Nessun dato
Gerhard Schaefer	Member of Advisory Board	11yrs	Nessun dato	Nessun dato
Colin Bond	Member of the Supervisory Board	less than a year	Nessun dato	Nessun dato
Nicholas Haggar	Deputy Chairman of the Supervisory Board	less than a year	Nessun dato	Nessun dato
Johannes Buchner	Member of Advisory Board	8.8yrs	Nessun dato	Nessun dato
Thomas Siklosi	Member of Advisory Board	6.3yrs	Nessun dato	Nessun dato
Klaus Rohrig	Member of Supervisory Board	3.9yrs	Nessun dato	Nessun dato
Wolfgang Essler	Chairman of the Supervisory Board	1.3yrs	Nessun dato	Nessun dato
Bodo Coldewey	Member of the Supervisory Board	less than a year	Nessun dato	Nessun dato

3.9yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0W4N sono considerati esperti (durata media dell'incarico 3.9 anni).

Formycon Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Formycon AG Appoints Colin Bond as Director

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Now 24% undervalued

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

New minor risk - Shareholder dilution

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings released: €1.22 loss per share (vs €0.54 loss in FY 2020)

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media